logo
ProjectArchived

Alzheimer's Drug-Development Program (U01)

Sector: Manufacturing (Industrial) • Location: United States of America

Source: Grants.gov

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such

Status
Closed
Sector
Manufacturing (Industrial), Chemical (Industrial), Hospital, Rail, Government, Education, Hotel
Location
United States of America
Updated
22 Jul 2026
Source
Grants.gov

ConstructChat

Ask ConstructChat about Alzheimer's Drug-Development Program (U01)

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Alzheimer's Drug-Development Program (U01)” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in United States of America. Taiyo aggregates data on it from Grants.gov.

Participants

Sponsoring Agency

Status

Original status

archived

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization.

Location

Country

United States of America (USA)

Source

Source reliability

High

Source

Grants.gov

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Chemical (Industrial), Hospital, Rail, Government, Education, Hotel

Article published date

2023-06-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project